Skip to main content

FEATURED

Letter from our Director

In 2023, we remain committed to our institution’s mission of promoting and managing research in close collaboration with the Vall d’Hebron Hospital. This is why we can be proud of our high-level clinical, translational and basic research, which covers all areas of human health and disease and all stages of life, from before birth to old age.

I would like to start by highlighting 2 milestones at the institutional level this year, such as the CERCA evaluation and the first phase of re-accreditation as a research institute by the Instituto de Salud Carlos III.

Top Scientific Advances

Discover some of the main research results that we have achieved during 2023.

2389
Total Staff
1199B2
Research Staff
icon-women-staff-02
65.6
Women Staff
icon-number-publications-02
1574
Number of Publications
icon-impact-factor-03
14393
Total Impact Factor
icon-leadership-02
50.2
Publications Leadership
icon-new-projects-03
220
New Project & HR Grants
icon-grants-funding-02
25.44
Grants Funding
icon-ongoing-projects-03
485
Ongoing Projects
icon-new-clinical-02
266
New Clinical Studies
icon-active-clinical-02
1080
Active Clinical Studies
icon-new-patient-03
834
New Patient Inclusion
icon-licensed-patents-02
35
Licensed Patents
icon-spin-off-02
2
Spin-offs/Start-ups Approved
icon-revenue-innovation-02
1.23
Revenue from Innovation

TOP STORIES

HIGHLIGHTS

eCORE

Global Health

malalties-infeccioses
496
Publications
4287
Impact Factor
8.64
Average Impact Factor
57.1
%Q1

Brain & Mind and Behaviour

Research groups affiliated to this eCORE are focused on the study of diseases affecting the brain, mind and/or behaviour. These clinical conditions have a high personal, social and economic burden, leading to disability and reducing quality and life.

RESEARCH GROUPS

335
Publications
2694
Impact Factor
8.04
Average Impact Factor
63.0
%Q1

Cancer

The aim of the Cancer eCORE is to improve the outcome and quality of life of cancer patients. Cancer eCORE directs its efforts to unveil and understand the mechanisms of the cancer origin and progression. The ultimate goal is to translate this knowledge into new diagnostic, prognostic and therapeutic solutions. Our bench to bed comprehensive research includes the generation of relevant disease models, biomarker studies, drug development and clinical trials.

RESEARCH GROUPS

oncologia_0
327
Publications
2644
Impact Factor
8.09
Average Impact Factor
55.7
%Q1

BEST SCIENTIFIC IMAGES

PARTNERS AND ACKNOWLEDGEMENTS

In this section we want to thank the support of the board of trustees and other governing bodies, the entities that have placed their trust in us by financing research projects, as well as all the citizens and patient’s associations because through their private donations they contribute to providing research funds. And, finally, to the patients and their families for their generosity in helping us on a day-to-day basis, whether in defining our mission, placing themselves at the center of research since they are the first to benefit, either as volunteers in the clinical trials.

VHIR Annual Report 2023